References of "Belaiche, Jacques"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailTailoring the treatment to the individual in Crohn's disease
Louis, Edouard ULg; Belaiche, Jacques ULg; Reenaers, Catherine ULg

in Therapeutic advances in Gastroenterology (2009), 2

Detailed reference viewed: 20 (2 ULg)
Full Text
Peer Reviewed
See detailGenetics of ulcerative colitis: the come-back of interleukin 10.
Louis, Edouard ULg; Libioulle, Cécile ULg; Reenaers, Catherine ULg et al

in Gut (2009), 58(9), 1173-6

Detailed reference viewed: 42 (7 ULg)
Full Text
Peer Reviewed
See detailThérapies biologiques et maladies inflammatoires chroniques intestinales
Reenaers, Catherine ULg; Louis, Edouard ULg; Belaiche, Jacques ULg

in Revue Médicale de Liège (2009), 64(5-6), 301-304

Detailed reference viewed: 45 (3 ULg)
Full Text
Peer Reviewed
See detailGuillain-Barré syndrome following hepatitis E
Loly, Jean-Philippe ULg; Rikir, Estelle ULg; Seivert, Maxime ULg et al

in World Journal of Gastroenterology (2009), 15(13), 1645-1647

Guillain-Barré syndrome (GBS) is often triggered by a preceding bacterial or viral infection. Occasionally, it has been observed in association with acute hepatitis A, B and C, and three cases have been ... [more ▼]

Guillain-Barré syndrome (GBS) is often triggered by a preceding bacterial or viral infection. Occasionally, it has been observed in association with acute hepatitis A, B and C, and three cases have been previously described in India in which GBS was associated with acute hepatitis E. A molecular mimicry mechanism is supposed to be involved in the pathogenesis of GBS triggered by infectious agents, although the nature of the shared epitopes has not been characterized in most instances, including that in the case of hepatotropic viruses. We report a case of GBS following acute hepatitis E in a European individual. The presence of antiganglioside GM2 antibodies in this patient suggested molecular mimicry involving ganglioside GM2 in the pathogenesis of GBS associated with hepatitis E. [less ▲]

Detailed reference viewed: 60 (7 ULg)
Full Text
Peer Reviewed
See detailPredictors of severe Crohn's disease
Loly, Catherine ULg; Belaiche, Jacques ULg; Louis, Edouard ULg

in Scandinavian Journal of Gastroenterology (2008), 43(8), 948-54

Detailed reference viewed: 64 (12 ULg)
Full Text
Peer Reviewed
See detailGastroenterology - Clinical and genetic factors associated with sacroiliitis in Crohn's disease
Peeters, Harald; Cruyssen, Bert Vander; Mielants, Herman et al

in Journal of Gastroenterology and Hepatology (2008), 23(1), 132-137

Background and Aim: Radiographic sacroiliitis (SI), often asymptomatic, is considered the most frequent extra-intestinal manifestation (EIM) of Crohn's disease (CD). Data on the association of SI with ... [more ▼]

Background and Aim: Radiographic sacroiliitis (SI), often asymptomatic, is considered the most frequent extra-intestinal manifestation (EIM) of Crohn's disease (CD). Data on the association of SI with other clinical features of CD are limited. Association of SI with CARD15 polymorphisms has recently been suggested. In a multicenter study, we investigated the association of SI in CD patients with clinical phenotypes, other EIM and CARD15 polymorphisms. Methods: Radiographs of the sacroiliac joints were taken in 251 CD patients from three Belgian university hospitals and scored by two blinded rheumatologists. Clinical features were obtained from medical records. Forty-three percent of patients carried at least one CARD15 polymorphism. Results: Sacroiliitis, defined as the presence of at least grade 2 unilateral changes, was diagnosed in 65 of the 244 scorable radiographs (27%). Only 16 of these patients were previously diagnosed with ankylosing spondylitis (AS). HLA-B27 positivity was observed in 53% of patients with AS and 7% of patients with radiographic SI. In univariate and multivariate analysis, associations between the presence of SI and peripheral arthritis (P = 0.005) and between AS and uveitis (P = 0.005) were found. No associations with other recorded clinical features or with CARD15 polymorphisms were observed. Conclusion: We confirm the high prevalence of radiographic sacroiliitis in a multicenter CD cohort. Uveitis is only associated with AS whereas all patients with SI are more prone to develop peripheral arthritis during their disease course, suggesting similar pathogenetic mechanisms in the development of these EIM. The previously reported association between SI and CARD15 polymorphisms was not confirmed. [less ▲]

Detailed reference viewed: 43 (3 ULg)
Full Text
Peer Reviewed
See detailProteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study.
Meuwis, Marie-Alice ULg; Fillet, Marianne ULg; Lutteri, Laurence ULg et al

in Clinical Biochemistry (2008), 41(12), 960-7

OBJECTIVES: Infliximab is the first anti-TNFalpha accepted by the Food and Drug Administration for use in inflammatory bowel disease treatment. Few clinical, biological and genetic factors tend to predict ... [more ▼]

OBJECTIVES: Infliximab is the first anti-TNFalpha accepted by the Food and Drug Administration for use in inflammatory bowel disease treatment. Few clinical, biological and genetic factors tend to predict response in Crohn's disease (CD) patient subcategories, none widely predicting response to infliximab. DESIGN AND METHODS: Twenty CD patients showing clinical response or non response to infliximab were used for serum proteomic profiling on Surface Enhanced Lazer Desorption Ionisation-Time of Flight-Mass Spectrometry (SELDI-TOF-MS), each before and after treatment. Univariate and multivariate data analysis were performed for prediction and characterization of response to infliximab. RESULTS: We obtained a model of classification predicting response to treatment and selected relevant potential biomarkers, among which platelet aggregation factor 4 (PF4). We quantified PF4, sCD40L and IL-6 by ELISA for correlation studies. CONCLUSIONS: This first proteomic pilot study on response to infliximab in CD suggests association between platelet metabolism and response to infliximab and requires validation studies on a larger cohort of patients. [less ▲]

Detailed reference viewed: 116 (25 ULg)
Full Text
Peer Reviewed
See detailDoes the behavior of Crohn's disease change over time?
Louis, Edouard ULg; Reenaers, Catherine ULg; Belaiche, Jacques ULg

in Inflammatory Bowel Diseases (2008), 14

Detailed reference viewed: 32 (7 ULg)
Full Text
Peer Reviewed
See detailAre we giving biologics too much time? When should we stop treatment?
Louis, Edouard ULg; Reenaers, Catherine ULg; Belaiche, Jacques ULg

in World Journal of Gastroenterology (2008), 14

Detailed reference viewed: 17 (4 ULg)
Full Text
Peer Reviewed
See detailGenome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
Barrett, Jeffrey C.; Hansoul, Sarah ULg; Nicolae, Dan L. et al

in Nature Genetics (2008), 40(8), 955-62

Several risk factors for Crohn's disease have been identified in recent genome-wide association studies. To advance gene discovery further, we combined data from three studies on Crohn's disease (a total ... [more ▼]

Several risk factors for Crohn's disease have been identified in recent genome-wide association studies. To advance gene discovery further, we combined data from three studies on Crohn's disease (a total of 3,230 cases and 4,829 controls) and carried out replication in 3,664 independent cases with a mixture of population-based and family-based controls. The results strongly confirm 11 previously reported loci and provide genome-wide significant evidence for 21 additional loci, including the regions containing STAT3, JAK2, ICOSLG, CDKAL1 and ITLN1. The expanded molecular understanding of the basis of this disease offers promise for informed therapeutic development. [less ▲]

Detailed reference viewed: 122 (42 ULg)
Full Text
Peer Reviewed
See detailL'hépatite E : une hépatite du tiers-monde présente en Belgique
Seivert, Maxime ULg; Belaiche, Jacques ULg; Delwaide, Jean ULg

in Revue Médicale de Liège (2008), 63

Detailed reference viewed: 124 (14 ULg)
Full Text
See detailL'oesophagite à éosinophiles chez l'adulte : à propos d'un cas
Marting, Audrey ULg; Leclercq, Philippe ULg; Gast, Pierrette ULg et al

in Revue Médicale de Liège (2008), 63

Detailed reference viewed: 207 (6 ULg)
Full Text
See detailManifestations respiratoires de la rectocolite ulcérohémorragique et de la maladie de Crohn
Guiot, Julien; Louis, Edouard ULg; Belaiche, Jacques ULg et al

in EMC Pneumologie (2008)

Detailed reference viewed: 138 (9 ULg)
Full Text
Peer Reviewed
See detailSensitivity of intestinal fibroblasts to TNF-related apoptosis-inducing ligand-mediated apoptosis in Crohn's disease
Reenaers, Catherine ULg; Franchimont, Nathalie; Oury, Cécile ULg et al

in Scandinavian Journal of Gastroenterology (2008), 43

Detailed reference viewed: 57 (15 ULg)
Full Text
Peer Reviewed
See detailAn insertion-deletion polymorphism in the Interferon Regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases
Dideberg, Vinciane ULg; Kristjansdottir, G.; Milani, L. et al

in Human Molecular Genetics (2007), 16(24), 3008-3016

The interferon regulatory factor 5 (IRF5) gene encodes a transcription factor that plays an important role in the innate as well as in the cell-mediated immune responses. The IRF5 gene has been shown to ... [more ▼]

The interferon regulatory factor 5 (IRF5) gene encodes a transcription factor that plays an important role in the innate as well as in the cell-mediated immune responses. The IRF5 gene has been shown to be associated with systemic lupus erythematosus and rheumatoid arthritis. We studied whether the IRF5 gene is also associated with inflammatory bowel diseases (IBD), Crohn disease (CD) and ulcerative colitis (UC). Twelve polymorphisms in the IRF5 gene were genotyped in a cohort of 1007 IBD patients (748 CD and 254 UC) and 241 controls from Wallonia, Belgium. The same polymorphisms were genotyped in a confirmatory cohort of 311 controls and 687 IBD patients (488 CD and 192 UC) from Leuven, Belgium. A strong signal of association [P=1.9x10(-5), odds ratio (OR) 1.81 (1.37-2.39)] with IBD was observed for a 5 bp indel (CGGGG) polymorphism in the promoter region of the IRF5 gene. The association was detectable also in CD patients (P=6.8x10(-4)) and was particularly strong among the UC patients [P=5.3x10(-8), OR=2.42 (1.76-3.34)]. The association of the CGGGG indel was confirmed in the second cohort [P=3.2x10(-5), OR=1.59 (1.28-1.98)]. The insertion of one CGGGG unit is predicted to create an additional binding site for the transcription factor SP1. Using an electrophoretic mobility shift assay, we show allele-specific differences in protein binding to this repetitive DNA-stretch, which suggest a potential function role for the CGGGG indel. [less ▲]

Detailed reference viewed: 34 (0 ULg)
Full Text
Peer Reviewed
See detailAssessment of endoscopic activity lndex and biological lnflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level
Denis, Marie-Armelle; Reenaers, Catherine ULg; Fontaine, Fernand et al

in Inflammatory Bowel Diseases (2007), 13(9), 1100-1105

Background: Patients with clinically active Crohn's disease (CD), defined by a Crohn's Disease Activity Index (CDAI) > 150, may have normal Greactive protein (CRP) serum levels. In such cases, it is ... [more ▼]

Background: Patients with clinically active Crohn's disease (CD), defined by a Crohn's Disease Activity Index (CDAI) > 150, may have normal Greactive protein (CRP) serum levels. In such cases, it is difficult to know whether these patients have really active disease or rather functional symptoms. This distinction is important to decide the most appropriate treatment. The aim of our work was to assess intestinal and colonic lesions in such patients and to look for biological markers potentially associated with endoscopic activity of the disease. Methods: We included 28 consecutive CD patients with CDAI >150 and a normal CRP level. These patients underwent a full colonoscopy with Crohn's Disease Endoscopy Index of Severity (CDEIS) calculation, fecal calprotectin, blood fibrinogen, acid a-I glycoprotein, and erythrocyte sedimentation rate measurement. The Harvey-Bradshaw score was also calculated. Serum ILI beta, IL6, IL8, sIL2R, and sTNFR2 were measured. Results: The median CDAI was 181 (151-485). Almost all (92.9%) these patients had endoscopic lesions, but the majority had only mild lesions (CDEIS : 6). No correlation was found between CDEIS and any of the clinical or biological markers. However, all the patients with significant endoscopic lesions (defined by a CDEIS >6) had previous surgical intestinal resection and lesions involving the anastomosis. Conclusions: Patients with elevated CDAT and normal CRP have only mild mucosal lesions of CD. Most significant lesions may be observed at the anastomosis and proximal to it in previously operated patients. None of the biological markers tested was associated with these endoscopic lesions. [less ▲]

Detailed reference viewed: 31 (1 ULg)
Full Text
Peer Reviewed
See detailThe role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases
De Jager, P. L.; Franchimont, D.; Waliszewska, A. et al

in Genes and Immunity (2007), 8(5), 387-397

The intestinal flora has long been thought to play a role either in initiating or in exacerbating the inflammatory bowel diseases (IBD). Host defenses, such as those mediated by the Toll-like receptors ... [more ▼]

The intestinal flora has long been thought to play a role either in initiating or in exacerbating the inflammatory bowel diseases (IBD). Host defenses, such as those mediated by the Toll-like receptors (TLR), are critical to the host/pathogen interaction and have been implicated in IBD pathophysiology. To explore the association of genetic variation in TLR pathways with susceptibility to IBD, we performed a replication study and pooled analyses of the putative IBD risk alleles in NFKB1 and TLR4, and we performed a haplotype-based screen for association to IBD in the TLR genes and a selection of their adaptor and signaling molecules. Our genotyping of 1539 cases of IBD and pooled analysis of 4805 cases of IBD validates the published association of a TLR4 allele with risk of IBD (odds ratio (OR): 1.30, 95% confidence interval (CI): 1.15 - 1.48; P = 0.00017) and Crohn's disease (OR: 1.33, 95% CI: 1.16 - 1.54; P = 0.000035) but not ulcerative colitis. We also describe novel suggestive evidence that TIRAP (OR: 1.16, 95% CI: 1.04 - 1.30; P = 0.007) has a modest effect on risk of IBD. Our analysis, therefore, offers additional evidence that the TLR4 pathway - in this case, TLR4 and its signaling molecule TIRAP - plays a role in susceptibility to IBD. [less ▲]

Detailed reference viewed: 23 (3 ULg)
Full Text
Peer Reviewed
See detailNoninvasive assessment of Crohn's disease intestinal lesions with F-18-FDG PET/CT
Louis, Edouard ULg; Ancion, Geoffrey; Colard, Arnaud et al

in Journal of Nuclear Medicine (2007), 48(7), 1053-1059

Pilot studies have shown good sensitivity and specificity for F-18-FDG PET in detecting gastrointestinal lesions of Crohn's disease. The combination of F-18-FDG PET with CT may further improve the ... [more ▼]

Pilot studies have shown good sensitivity and specificity for F-18-FDG PET in detecting gastrointestinal lesions of Crohn's disease. The combination of F-18-FDG PET with CT may further improve the localization and characterization of lesions with increased F-18-FDG uptake. Our aim was to assess the use of F-18-FDG PET/CT in evaluating the activity and location of Crohn's disease along the gastrointestinal tract. Methods: After giving informed consent, 22 patients with Crohn's disease were prospectively studied. They underwent F-18-FDG PET/CT, followed by ileocolonoscopy within 1 wk (mean, 2 d). The Crohn's disease activity index (CDAI) was calculated, and serum C-reactive protein (CRP) and fecal calprotectin were measured before endoscopy. The Crohn's disease endoscopy index of severity (CDEIS) was calculated during endoscopy. The global CDEIS score and endoscopic subscores for various ileocolonic segments were used for analysis. Results: Globally, 95 intestinal and colonic segments in 22 patients were analyzed. F-18-FDG PET/CT detected 35 of 48 endoscopically affected segments (sensitivity for the detection of endoscopic lesions, 72.9%). The sensitivity of F-18-FDG PET/CT for the detection of severe endoscopic lesions (deep ulcers and strictures) was 100% (14/14). The global PET/CT score significantly correlated with CDEIS (r = 0.51; 95% confidence interval [Cl], 0.09-0.77; P = 0.017), CDAI (r = 0.58; 95% Cl, 0.17-0.80; P = 0.005), and CRP (r = 0.56; 95% Cl, 0.19-0.81; P = 0.007). Conclusion: F-18-FDG PET/CT was globally well correlated to the clinical, endoscopic, and biologic activity of Crohn's disease. Above all, this technique had a good sensitivity for the detection of intestinal and colonic segments with moderate to severe mucosal lesions. The potential impact of this promising tool on the global management of patients with Crohn's disease should be further evaluated in prospective studies. [less ▲]

Detailed reference viewed: 53 (8 ULg)